SoFi shares rise as record revenue, member growth drive strong Q3 results
Investing.com -- DexCom (NASDAQ:DXCM) stock fell 4% Tuesday after a concerning report from Hunterbrook detailed multiple deaths allegedly linked to the company’s G7 continuous glucose monitor.
The Hunterbrook report highlighted three deaths reported to the FDA in September following issues with DexCom ’s G7 device. According to FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, at least 13 G7 users have died since the product’s launch in 2023. The report noted cases where sensors allegedly failed to show readings or displayed inaccurate blood sugar levels.
The investigation also revealed that endocrinologists across the country have reported repeated G7 failures to Hunterbrook. The report included testimony from an ICU nurse who was hospitalized after her G7 device allegedly showed an inaccurate reading, causing her to experience dangerously low blood sugar levels.
This latest development follows Hunterbrook’s previous investigation published in September, which prompted a sharp stock decline and led to multiple class action lawsuits against DexCom. The lawsuits claim the company’s devices were not as accurate as advertised. Additionally, a securities lawsuit was filed against the company recently.
The FDA sent DexCom a warning letter in March 2025, and the company reportedly issued a recall for receivers that didn’t sound alarms as expected.
DexCom is scheduled to report earnings later this week but did not respond to Hunterbrook’s requests for comment regarding the reported deaths.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.